ESMO Breast 2020 | Effects of BMI on PFS in the MONARCH 1 and MONARCH 2 trial

Evandro de Azambuja, MD, PhD, of the Institut Jules Bordet, Brussels, Belgium, reports small decreases in PFS for obese patients treated with CDK4/6 inhibitors and endocrine therapy in the MONARCH 1 (NCT02102490) and MONARCH 2 (NCT02107703) trials. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).